Truist Financial analyst Richard Newitter maintained a Hold rating on Inari Medical (NARI – Research Report) yesterday and set a price target of $63.00. The company’s shares closed yesterday at $57.01.
Newitter covers the Healthcare sector, focusing on stocks such as Stryker, Nevro Corp, and Inspire Medical Systems. According to TipRanks, Newitter has an average return of 17.3% and a 59.89% success rate on recommended stocks.
Currently, the analyst consensus on Inari Medical is a Strong Buy with an average price target of $78.13.
See the top stocks recommended by analysts >>
The company has a one-year high of $71.85 and a one-year low of $47.81. Currently, Inari Medical has an average volume of 801.9K.
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is neutral on the stock. Last month, William Hoffman, a Director at NARI bought 103,492.00 shares for a total of $43,466.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical (NARI) Company Description:
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI:
- Inari Medical initiated with a Buy at Needham
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M
- Inari Medical sees Q4 revenue at least $132M, consensus $130.98M
